印度的人乳头瘤病毒疫苗接种：批判性评估
HPV Vaccination in India: Critical Appraisal.
作者信息
Nigam Aruna, Saxena Pikee, Acharya Anita S, Mishra Archana, Batra Swaraj
机构信息
Department of Obstetrics and Gynaecology, Hamdard Institute of Medical Sciences and Research, New Delhi 110062, India ; Reader's Flat No. 4, Lady Hardinge Medical College Campus, New Delhi 110001, India.
Department of Obstetrics and Gynaecology, Lady Hardinge Medical College, New Delhi 110001, India.
出版信息
ISRN Obstet Gynecol. 2014 Mar 11;2014:394595. doi: 10.1155/2014/394595. eCollection 2014.
Cervical cancer is the third most common cancer in women worldwide. The role of human papilloma virus (HPV) in the genesis of cervical carcinoma is well documented. The HPV 16 and 18 are found to be most commonly associated with invasive cervical carcinoma. The advent of cervical carcinoma vaccine has advanced the hopes that eradication of cervical carcinoma might be possible in future. The scenario of prevention of cervical carcinoma is completely different in developed and developing countries. The implementation of the vaccination as a routine in India is still controversial. Here we have tried to critically analyse these issues in Indian context. However it is clear that cervical cancer vaccine is not an immediate panacea and cannot replace the cervical cancer screening which is mandatory in Indian context.
宫颈癌是全球女性中第三大常见癌症。人乳头瘤病毒（HPV）在宫颈癌发生过程中的作用已有充分记录。已发现HPV 16和18最常与浸润性宫颈癌相关。宫颈癌疫苗的出现让人们燃起了未来有可能根除宫颈癌的希望。发达国家和发展中国家预防宫颈癌的情况完全不同。在印度将疫苗接种作为常规措施实施仍存在争议。在此，我们试图在印度背景下对这些问题进行批判性分析。然而，很明显宫颈癌疫苗并非立竿见影的万灵药，也无法取代在印度背景下强制进行的宫颈癌筛查。
Zotero 插件